Mesothelin, a novel immunotherapy target for triple negative breast cancer
- 15 March 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 133 (2), 799-804
- https://doi.org/10.1007/s10549-012-2018-4
Abstract
Mesothelin is a cell-surface glycoprotein present on mesothelial cells and elicits T cell responses in a variety of cancers including pancreatic, biliary and ovarian cancer. Breast cancer is not known to express mesothelin. We postulated that mesothelin may be a unique tumor-associated antigen in triple negative breast cancer (TNBC), a less common breast cancer subtype which may have been under-represented in prior studies that characterized mesothelin expression. Therefore, we screened 99 primary breast cancer samples by immunohistochemistry analysis using formalin-fixed paraffin-embedded archival tumor tissues and confirmed that mesothelin was overexpressed in the majority of TNBC (67 %) but only rarely in p < 0.001). Our results suggest that mesothelin has promise as a novel immunotherapy target for TNBC for which effective targeted therapy is lacking to date.Keywords
This publication has 17 references indexed in Scilit:
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid LeukemiaThe New England Journal of Medicine, 2011
- Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody ReceptorClinical Cancer Research, 2011
- Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated TumorCancer Research, 2010
- Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domainsProceedings of the National Academy of Sciences of the United States of America, 2009
- Heterogeneity of Breast Cancer Metastases: Comparison of Therapeutic Target Expression and Promoter Methylation Between Primary Tumors and Their Multifocal MetastasesClinical Cancer Research, 2008
- Mesothelin targeted cancer immunotherapyEuropean Journal Of Cancer, 2008
- A collection of breast cancer cell lines for the study of functionally distinct cancer subtypesCancer Cell, 2006
- Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiationThe Journal of Pathology, 2006
- Value of Mesothelin Immunostaining in the Diagnosis of MesotheliomaLaboratory Investigation, 2003
- Monoclonal Antibody K1 Reacts With Epithelial Mesothelioma but not With Lung AdenocarcinomaThe American Journal of Surgical Pathology, 1992